Infographic: How Aware of Biosimilars are US Rheumatologists?

A recent survey of US rheumatologists found that there is room for improvement in clinicians' awareness of biosimilar therapies.

Related Content:

RheumatologyPractice

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

Consumers and Providers Face Biosimilar Knowledge Hurdles

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA